Bristol Myers Squibb has named Dr. Cristian Massacesi as its new Executive Vice President and Chief Medical Officer, overseeing all stages of drug development starting August 1, 2025. With over 20 years of experience in cancer research and drug development, Dr. Massacesi will lead the company’s efforts to create new treatments. He previously worked at AstraZeneca, Alexion, Pfizer, and Novartis, helping bring many new medicines to patients. Dr. Massacesi replaces Dr. Samit Hirawat, who will stay on as an advisor until November 1, 2025. The company’s CEO, Christopher Boerner, praised Dr. Massacesi’s expertise, saying he will help advance breakthrough medicines for patients worldwide. Dr. Massacesi shared his mission to find new treatments for difficult diseases, ensuring no patient is ever told there are no options left.